ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Janssen signs JAK pact with Theravance

by Ryan Cross
February 12, 2018 | APPEARED IN VOLUME 96, ISSUE 7

Interest in inhibiting the Janus kinase (JAK) family of enzymes to reduce cytokine-induced inflammation continues to grow. Janssen Biotech, a division of Johnson & Johnson, has signed a pact to codevelop and commercialize an anti-JAK compound from Theravance Biopharma called TD-1473. This year, Theravance will test TD-1473, designed to work primarily in the gastrointestinal tract, in a Phase IIb/III study in ulcerative colitis and a Phase II study in Crohn’s disease. Janssen will pay Theravance $100 million up front and up to $900 million more in milestone payments. Just last month, Celgene acquired Impact Biosciences for its JAK2 inhibitor fedratinib.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment